DNA GTx partners GROINN to develop network of data for agriculture and forestry, achieves two prestigious accreditations
UAE – DNA GTx, a leading bioinformatics-based biotech company, has signed a Memorandum of Understanding (MoU) with GROINN, a leading company in the realm of digital agriculture, to develop a network of data for agriculture and forestry and provide predictive analytics.
The MoU strives to apply cutting-edge techniques and advances for agriculture and forestry while complementing each company’s goals.
Together, omics technologies like metagenomics will be an ally to the predictive analytics necessary for improving crop yield, pest management and more.
“This collaboration means the integration of advanced omics and bioinformatics technologies with cutting-edge agricultural practices. By partnering with GROINN, we are poised to leverage our combined expertise to optimize production, improve efficiency, and enhance product quality in agriculture.” said Sandro de Souza, CSO of DNA GTx.
“This alliance shows our commitment to driving innovation and sustainability, ultimately benefiting both the environment and society. We are excited about the potential this partnership holds for transforming agriculture and ensuring top-quality food production.”
Both companies will explore joint research and development initiatives that encompass potential applications to the analysis of soil and crop data, identification of drought or pest resistance in soil microbiome, indications of pest susceptibilities to minimize pesticide use, smart farming solutions, climate resilience and more.
Meanwhile, DNA GTx has achieved two prestigious accreditations: the ISO 15189 accreditation and the College of American Pathologists (CAP) accreditation.
The accreditations not only enhance the quality and reliability of DNA GTx’s operations but also contribute to improved patient outcomes by ensuring the highest standards of care.
DNA GTx said it will continue to uphold these rigorous standards and set a benchmark for other laboratories in the industry, paving the way for advancements in medical research and patient care.
DNA GTx has operations in the UAE, Brazil, and the USA, dedicated to advancing genomics.
DNA GTx aims to be a pivotal resource for both public and private sectors, offering expertise across genomics and proteomics in experimental and bioinformatics domains.
The company said it is equipped with advanced sequencing technologies, including Illumina and Oxford Nanopore Technologies (ONT), along with advanced propreitary bioinformatics tools such as the world class variant viewer, D-krypt™, GTx-Onco™, GTx-Proteo™, GTx-META™, GTx-RNA, etc..
“We prioritize innovation and development to keep our services aligned with the latest technological advancements in NGS,” DNA GTx LAB explained.
“Our work is disseminated through international collaborations and scientific communications, enhancing our visibility on both national and global stages.”
DNA GTx work’s closely with the healthcare sector through development of molecular diagnostics tests across multiple medical specialties such as oncology, WES, WGS, NIPT etc.